시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 빈다켈 시장 보고서(2025년)
Vyndaqel Global Market Report 2025
상품코드 : 1720928
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,618,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,566,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,515,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

빈다켈 시장 규모는 향후 수 년간 급성장이 전망될 예정입니다. 예측 기간 동안의 예상 성장은 연구 개발에 대한 투자 증가, 정밀 의학의 채택 증가, 의사에 대한 친숙도 증가, 진단 도구의 가용성 증가, 정부 이니셔티브 확대 등에 힘입은 것입니다. 주요 동향으로서는 원격 의료 시설의 확대, 전략적 제휴, 유전자 검사의 진보, 디지털 헬스 툴의 통합, 맞춤형 의료의 대두 등을 들 수 있습니다.

연구개발에 대한 투자 증가는 향후 몇 년간의 빈다켈 시장의 성장을 가속할 것으로 예측됩니다. 우리의 중요한 자금 제공 이니셔티브에 기인하고 있습니다. 연구 개발에 대한 투자는 치료법의 개발과 최적화를 가속화하고 환자의 접근성을 높이고 있습니다. 2024년 7월 영국에 본사를 둔 정부 부처인 보건사회복지부는 영국의 기업 부문이 2022년에 약 111억 달러 상당의 의약품의 연구 개발을 실시해, 이것은 국가의 국내총생산 0.36%에 해당한다고 보고했습니다.

또한 정밀의료의 채택 확대도 빈다켈 시장의 확대에 기여할 것으로 기대되고 있습니다. 맞춤형 의료는 유전적, 환경적, 생활 방식 요인에 따라 개별 환자에게 맞춤형 의료 서비스를 제공하는 것을 포함합니다. 이 접근 방식은 트랜스티레틴 아밀로이드증(ATTR)에 대한 보다 정밀한 진단과 표적 치료를 가능하게 하여 빈다켈에게 도움이 되며, 이 약물이 가장 큰 혜택을 받을 수 있는 환자에게 도달할 수 있도록 합니다. 의료 채용이 증가하고 시장 성장을 지원하고 빈다켈과 같은 전문적인 치료법에 대한 수요를 높이고 있습니다. 2024년 2월 미국 비영리 단체인 개인 맞춤 의학 연합(Personalized Medicine Coalition)은 미국 식품의약국(FDA)이 2023년에 희귀 질환 환자를 위한 16개의 새로운 개인 맞춤형 치료법을 승인했으며, 이는 2022년의 6건 승인에 비해 크게 증가한 수치라고 보고했습니다. 그 결과, 정밀 의학의 채택이 증가함에 따라 빈다켈 시장의 성장이 촉진되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 세계 시장 경쟁 벤치마킹과 대시보드

제32장 주요 인수합병(M&A)

제33장 최근 시장 동향

제34장 시장의 잠재력이 높은 국가, 전략

제35장 부록

SHW
영문 목차

영문목차

Vyndaqel, also known as tafamidis, is a medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition caused by the accumulation of misfolded transthyretin proteins. It works by stabilizing the transthyretin protein, preventing its misfolding and buildup in the heart. Vyndaqel helps reduce cardiovascular-related deaths and hospitalizations while improving the quality of life for patients with this progressive and potentially fatal disease.

The primary product types of Vyndaqel include Vyndaqel (tafamidis 20 mg) and Vyndamax (tafamidis 61 mg). Vyndaqel (tafamidis 20 mg) is a transthyretin stabilizer used to treat transthyretin amyloid polyneuropathy (ATTR-PN) by slowing disease progression. It is indicated for familial amyloid polyneuropathy (FAP) and wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Vyndaqel is distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

The vyndaqel market research report is one of a series of new reports from The Business Research Company that provides vyndaqel market statistics, including vyndaqel industry global market size, regional shares, competitors with a vyndaqel market share, detailed vyndaqel market segments, market trends and opportunities, and any further data you may need to thrive in the vyndaqel industry. This vyndaqel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vyndaqel market size has grown rapidly in recent years. It will grow from $1.62 billion in 2024 to $1.91 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth during the historic period can be attributed to increasing awareness of transthyretin amyloidosis, a rising prevalence of transthyretin-mediated amyloidosis cardiomyopathy, a greater focus on rare diseases, growing government support, an increase in clinical trials, and a growing geriatric population.

The vyndaqel market size is expected to see rapid growth in the next few years. It will grow to $3.67 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The projected growth in the forecast period is driven by increasing investment in research and development, the growing adoption of precision medicine, rising physician familiarity, greater availability of diagnostic tools, and expanding government initiatives. Key trends include the expansion of telemedicine facilities, strategic collaborations, advancements in genetic testing, the integration of digital health tools, and the rise of personalized medicine.

The increasing investment in research and development is expected to drive the growth of the Vyndaqel market in the coming years. Research and development involve innovating and enhancing products, services, or processes through systematic investigation and experimentation. The rise in R&D investment is attributed to the increasing prevalence of neurological disorders, advancements in medical technology, growing awareness and demand for innovative treatments, and significant funding initiatives from both government and private sectors. Investment in research and development accelerates the development and optimization of therapies, enhancing their efficacy and accessibility for patients. It fosters advancements in Vyndaqel, improving its effectiveness, availability, and potential for expanded indications. For example, in July 2024, the Department of Health and Social Care, a UK-based government department, reported that the business enterprise sector in the UK conducted pharmaceutical research and development worth approximately $11.1 billion in 2022, representing 0.36% of the nation's gross domestic product. As a result, increasing investment in research and development is fueling the expansion of the Vyndaqel market.

The growing adoption of precision medicine is also expected to contribute to the expansion of the Vyndaqel market. Personalized medicine involves tailoring medical treatments to individual patients based on their genetic, environmental, and lifestyle factors. The increasing adoption of personalized medicine is driven by advancements in genomic research, improved treatment efficacy, and the rising prevalence of chronic diseases. This approach benefits Vyndaqel by enabling more precise diagnosis and targeted treatment for transthyretin amyloidosis (ATTR), ensuring that the drug reaches patients who will benefit the most. By enhancing treatment efficacy and improving patient outcomes, the rising adoption of personalized medicine supports market growth and increases the demand for specialized therapies such as Vyndaqel. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, a significant increase from six approvals in 2022. As a result, the increasing adoption of precision medicine is driving the growth of the Vyndaqel market.

Major companies in the Vyndaqel market are expanding their production facilities to manufacture active pharmaceutical ingredients (APIs). Facility expansion involves increasing physical infrastructure, production capacity, or operational capabilities to accommodate growth, enhance efficiency, and meet rising demand. For example, in July 2024, Pfizer Inc., a US-based pharmaceutical company that manufactures Vyndaqel, inaugurated a $1 billion plant in Singapore's Tuas Biomedical Park. This new 429,000 sq ft facility will produce active pharmaceutical ingredients for Pfizer's cancer, pain, and antibiotic medications. As an extension of Pfizer's existing site, which has been operational for 20 years, the new facility is expected to create 250 highly skilled jobs. The plant has also been awarded a Green Mark Gold certification for its environmental sustainability efforts and aligns with Pfizer's commitment to achieving net-zero emissions by 2040.

The key player in the vyndaqel market is Pfizer Inc.

North America was the largest region in the vyndaqel market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vyndaqel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vyndaqel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vyndaqel market consists of sales of cardiovascular medications, neuropathy medications, anticoagulants and diuretics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vyndaqel Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vyndaqel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for vyndaqel ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vyndaqel market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Vyndaqel Market Characteristics

3. Vyndaqel Market Trends And Strategies

4. Vyndaqel Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vyndaqel Growth Analysis And Strategic Analysis Framework

6. Vyndaqel Market Segmentation

7. Vyndaqel Market Regional And Country Analysis

8. Asia-Pacific Vyndaqel Market

9. China Vyndaqel Market

10. India Vyndaqel Market

11. Japan Vyndaqel Market

12. Australia Vyndaqel Market

13. Indonesia Vyndaqel Market

14. South Korea Vyndaqel Market

15. Western Europe Vyndaqel Market

16. UK Vyndaqel Market

17. Germany Vyndaqel Market

18. France Vyndaqel Market

19. Italy Vyndaqel Market

20. Spain Vyndaqel Market

21. Eastern Europe Vyndaqel Market

22. Russia Vyndaqel Market

23. North America Vyndaqel Market

24. USA Vyndaqel Market

25. Canada Vyndaqel Market

26. South America Vyndaqel Market

27. Brazil Vyndaqel Market

28. Middle East Vyndaqel Market

29. Africa Vyndaqel Market

30. Vyndaqel Market Competitive Landscape And Company Profiles

31. Global Vyndaqel Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Vyndaqel Market

33. Recent Developments In The Vyndaqel Market

34. Vyndaqel Market High Potential Countries, Segments and Strategies

35. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기